Proqr Therapeutics B.V. (PRQR)

[Gpheart2016]

Headline reports positive results from phase 1/2 study but the results are actually disappointing and the stock is suffering as a result. Unfortunately, their protocol required studying patients who had already lost vision and that seems like a long shot. Their real target patients should be adolescents/teenagers who are just beginning to show evidence of retinal deterioration. If they demonstrated that treatment prevented vision loss.....a real miracle and a great benefit to mankind. It would require a longer study.